2021 Year in Review - Triple-Negative Breast Cancer

Patients with bladder cancer can be empowered to better cope with their diagnosis by providing them with supplemental information relating to their disease state, potential treatments, and patient support services.
Responses to first- and second-line chemotherapy regimens for metastatic urothelial carcinoma (mUC) have been less than satisfactory, creating an unmet need for new treatment options for this disease.
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.
In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer.
Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events.
Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy.
Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment.
Compelling efficacy data for sacituzumab govitecan-hziy results in FDA fast-track approval for its use in metastatic triple-negative breast cancer.
Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.
Page 1 of 2
Results 1 - 10 of 13

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country